ACROBiosystems (百普赛斯) reported strong interim results with recombinant protein revenue up 26% YoY and antibody reagents up 50.9% YoY, while advancing its AI-driven drug discovery platform.
ACROBiosystems is a key enabler of AI drug discovery with robust financials and expanding global reach, making it a compelling growth story.
Free preview — more China A-share & HK research · About Us · Legal & Privacy